This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Myopia. Measurement will happen over the course of Visit 1: Day 0.
This trial requires 100 total participants across 1 different treatment groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Based off the small sample size, micropsia is a common feature among adults which may be a result of aging, cigarette smoking, anxiety, or other unrecognized comorbidities. Future prospective studies are needed to characterize micropsia’s effects.
Micropsia can occur without an optical defect. If micropsia is associated with an occult lesion, the diagnosis of micropsia is made without undue concern for its etiology.
There exists no single treatment or set of treatments to reverse the perception of magnification in micropsia. Patients are often instructed to use visual cues, such as close-up of the objects or switching positions, to help them compensate.
A number of treatments with some success had been tried that included a variety of approaches including: (1) a change in the visual environment (vision therapy) of looking at the globe, which has proven to be effective in the treatment of micropsia; (2) surgery for treatment of the brainstem; (3) treatment of the visual cortex by excitatory (electro stimulation) or inhibitory (chemical therapy) stimulation by a variety of medications, and (4) stereotactic surgery. The surgical approaches of micropsia include: [electrophysiologically guided neurosurgery, (EAPNS) in a manner that was developed by Dr.
Micropsia describes vision of the optic disc and/or peripheral field defects. It is common to see the optic disc as being larger than the central fovea in patients with micropsia. Micropsia can vary from mild astigmatism to a full-blown macropsia. In both cases, micropsia is not a disease. It is a symptom of certain pathological conditions. Clinicians and scientists should be aware that micropsia has little do to do with disease but rather, it is the result of a combination of factors. These factors include retinal thickness, a high amount of retinal neural cell, and changes in the thickness of the retina, especially among those persons who suffer from cataract.
Micropsia can be caused due to a change in the refractive power of the retina, or in some people, a change in the axial length of the eye. This is in contrast with diplopia, which occurs because of changes in the shape of the visual field.
The majority of patients reported micropsia as non-symptomatic and in the benign range. As expected the number of patients with micropsia increases with age and with increasing BMI. The number of patients who suffer some form of vision disturbance should be taken into account when considering the diagnostic value of micropsia.
The latest developments in treatment for pathological use are now a big reality. The need for a fast recovery after surgical therapy is not a problem anymore.
[Not all eye diseases can be treated in clinical trials. Clinical trials can help guide the selection of treatments for specific ocular diseases.] When looking for treatment for micropsia, [Power] allows clinicians to find clinical trials that are the best for you and your family [in the short run]. However, patients and their families that want to receive treatment in the long run should make their decisions based on a careful review of all of the available clinical trials.
[The use of micropsia has improved physical function in a population of patients with micropsia, which suggests an improvement in the quality of life of this patient group. Further prospective collaborative work is needed to delineate the contribution of micropsia to the burden of disease, and to evaluate the role of micropsia in symptom dimensions and as a predictor of health service use and service use by patients with micropsia.
Results from a recent paper of the trial show that in patients with [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) who are undergoing interferon therapy, treatment does not increase the risk of myeloma progression, despite a trend to shorter survival compared with placebo.
This case demonstrates that a multidisciplinary approach to complicated cases of micropsia can be effective. While the initial use of visual correction strategies were successful in managing symptoms, they were ineffective in achieving complete resolution of micropsia. A multidisciplinary approach including surgeons, optometrists, oculo-optometric technicians, neuro-optometric technicians, nurses, and nutritionists was successful in achieving sustained symptom control.